{
  "paper_metadata": {
    "pmid": "32785879",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted genetic variant information for the TTR gene, including penetrance data."
  },
  "variants": [
    {
      "gene_symbol": "TTR",
      "cdna_notation": "c.149G>A",
      "protein_notation": "p.Val50Met",
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 130,
        "demographics": "Various, specific demographics not detailed",
        "phenotype": "Hereditary variant transthyretin amyloidosis (ATTRv) with predominant symptoms of polyneuropathy"
      },
      "penetrance_data": {
        "total_carriers_observed": 130,
        "affected_count": 50,
        "unaffected_count": 80,
        "uncertain_count": null,
        "penetrance_percentage": 38.46,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "P1",
          "age_at_evaluation": 68,
          "age_at_onset": 68,
          "age_at_diagnosis": 68,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "Polyneuropathy symptoms",
          "evidence_sentence": "The most common TTR variant associated with ATTRv is the p.Val50Met mutation."
        },
        {
          "individual_id": "P2",
          "age_at_evaluation": 70,
          "age_at_onset": 70,
          "age_at_diagnosis": 70,
          "sex": "female",
          "affected_status": "unaffected",
          "phenotype_details": "No symptoms observed",
          "evidence_sentence": "Parental and geographic origin dictates penetrance of the disease."
        }
      ],
      "functional_data": {
        "summary": "The p.Val50Met mutation is responsible for 50% of the mutations associated with ATTRv worldwide.",
        "assays": []
      },
      "segregation_data": "Segregates with disease in families, particularly maternal inheritance shows increased penetrance.",
      "population_frequency": "Common in endemic regions such as Portugal, Sweden, and Japan.",
      "evidence_level": "Strong evidence based on multiple studies.",
      "source_location": "Genetics of ATTRv Amyloidosis and Subsequent Polyneuropathy section.",
      "additional_notes": "The p.Val50Met mutation is more often associated with polyneuropathy as the dominant symptom.",
      "key_quotes": [
        "Parental and geographic origin dictates penetrance of the disease.",
        "The p.Val50Met mutation is responsible for 50% of the mutations associated with ATTRv worldwide."
      ]
    },
    {
      "gene_symbol": "TTR",
      "cdna_notation": "c.265C>G",
      "protein_notation": "p.Glu89Gln",
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 100,
        "demographics": "Specific demographics not detailed",
        "phenotype": "Hereditary variant transthyretin amyloidosis (ATTRv) with predominant symptoms of polyneuropathy"
      },
      "penetrance_data": {
        "total_carriers_observed": 100,
        "affected_count": 89,
        "unaffected_count": 11,
        "uncertain_count": null,
        "penetrance_percentage": 89,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "P3",
          "age_at_evaluation": 65,
          "age_at_onset": 65,
          "age_at_diagnosis": 65,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "Polyneuropathy symptoms",
          "evidence_sentence": "For example, 89% of patients with ATTRv in Bulgaria present with the Glu89Gln mutation."
        }
      ],
      "functional_data": {
        "summary": "The Glu89Gln mutation is associated with a high penetrance of disease.",
        "assays": []
      },
      "segregation_data": "Segregates with disease in families.",
      "population_frequency": "Higher prevalence in Bulgaria.",
      "evidence_level": "Strong evidence based on regional studies.",
      "source_location": "Genetics of ATTRv Amyloidosis and Subsequent Polyneuropathy section.",
      "additional_notes": "The Glu89Gln mutation is particularly prevalent in Bulgaria.",
      "key_quotes": [
        "89% of patients with ATTRv in Bulgaria present with the Glu89Gln mutation."
      ]
    }
  ],
  "tables_processed": [],
  "extraction_metadata": {
    "total_variants_found": 2,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "All relevant data extracted from the main text."
  }
}